Can Kurt K, Kurt H, Tokuc E, Ozbey D, Arabaci D, Aydin S
Sci Rep. 2025; 15(1):6551.
PMID: 39994360
PMC: 11850609.
DOI: 10.1038/s41598-025-91073-1.
Mehmood Z, Kanwar R, Ullah K, Ali S, Aslam M, Qadeer A
Ir J Med Sci. 2025; .
PMID: 39912979
DOI: 10.1007/s11845-025-03898-4.
Steiner L, Schmittmann L, Rahn T, Lachnit T, Jahn M, Hentschel U
Environ Microbiome. 2024; 19(1):97.
PMID: 39593141
PMC: 11590407.
DOI: 10.1186/s40793-024-00637-7.
Bessems L, Chen B, Uyttebroek S, Devolder D, Lood C, Verwimp S
Front Cell Infect Microbiol. 2024; 14:1434397.
PMID: 39290977
PMC: 11405300.
DOI: 10.3389/fcimb.2024.1434397.
Bullen N, Johnson C, Andersen S, Arya G, Marotta S, Lee Y
Nat Commun. 2024; 15(1):6955.
PMID: 39138193
PMC: 11322646.
DOI: 10.1038/s41467-024-51346-1.
Emerging Microorganisms and Infectious Diseases: One Health Approach for Health Shared Vision.
Ristori M, Guarrasi V, Soda P, Petrosillo N, Gurrieri F, Longo U
Genes (Basel). 2024; 15(7).
PMID: 39062687
PMC: 11275270.
DOI: 10.3390/genes15070908.
Enterococcus Phage vB_EfaS_HEf13 as an Anti-Biofilm Agent Against Enterococcus faecalis.
Lee D, Im J, Kim A, Jun W, Yun C, Han S
J Microbiol. 2024; 62(8):683-693.
PMID: 38935316
DOI: 10.1007/s12275-024-00150-z.
Isolation and identification of a novel phage targeting clinical multidrug-resistant isolates.
Wang J, Zhang M, Pei J, Yi W, Fan L, Wang C
Front Cell Infect Microbiol. 2024; 14:1361045.
PMID: 38572320
PMC: 10987712.
DOI: 10.3389/fcimb.2024.1361045.
Ribosome profiling reveals downregulation of UMP biosynthesis as the major early response to phage infection.
OConnor P, Mahony J, Casey E, Baranov P, Van Sinderen D, Yordanova M
Microbiol Spectr. 2024; 12(4):e0398923.
PMID: 38451091
PMC: 10986495.
DOI: 10.1128/spectrum.03989-23.
Microbiome Dynamics: A Paradigm Shift in Combatting Infectious Diseases.
Kamel M, Aleya S, Alsubih M, Aleya L
J Pers Med. 2024; 14(2).
PMID: 38392650
PMC: 10890469.
DOI: 10.3390/jpm14020217.
Freeze-Drying of Encapsulated Bacteriophage T4 to Obtain Shelf-Stable Dry Preparations for Oral Application.
Sliwka P, Skaradzinski G, Dusza I, Grzywacz A, Skaradzinska A
Pharmaceutics. 2023; 15(12).
PMID: 38140132
PMC: 10747124.
DOI: 10.3390/pharmaceutics15122792.
An enterococcal phage protein broadly inhibits type IV restriction enzymes involved in antiphage defense.
Bullen N, Johnson C, Andersen S, Arya G, Marotta S, Lee Y
bioRxiv. 2023; .
PMID: 38014348
PMC: 10680825.
DOI: 10.1101/2023.11.16.567456.
The Potential of Bacteriophage Therapy as an Alternative Treatment Approach for Antibiotic-Resistant Infections.
Walter N, Mirzaei M, Deng L, Willy C, Alt V, Rupp M
Med Princ Pract. 2023; 33(1):1-9.
PMID: 37879316
PMC: 10896615.
DOI: 10.1159/000534717.
The long and sinuous road to phage-based therapy of infections.
Umansky A, Fortier L
Front Med (Lausanne). 2023; 10:1259427.
PMID: 37680620
PMC: 10481535.
DOI: 10.3389/fmed.2023.1259427.
A novel lytic phage exhibiting a remarkable in vivo therapeutic potential and higher antibiofilm activity against Pseudomonas aeruginosa.
Abdelghafar A, El-Ganiny A, Shaker G, Askoura M
Eur J Clin Microbiol Infect Dis. 2023; 42(10):1207-1234.
PMID: 37608144
PMC: 10511388.
DOI: 10.1007/s10096-023-04649-y.
Emerging applications of phage therapy and fecal virome transplantation for treatment of Clostridioides difficile infection: challenges and perspectives.
Raeisi H, Noori M, Azimirad M, Mohebbi S, Aghdaei H, Yadegar A
Gut Pathog. 2023; 15(1):21.
PMID: 37161478
PMC: 10169144.
DOI: 10.1186/s13099-023-00550-3.
Potential application of a newly isolated phage BUCT609 infecting .
Han K, Dong Y, An X, Song L, Li M, Fan H
Front Microbiol. 2022; 13:1001237.
PMID: 36478859
PMC: 9720304.
DOI: 10.3389/fmicb.2022.1001237.
Structure and host specificity of bacteriophage Andhra.
Hawkins N, Kizziah J, Hatoum-Aslan A, Dokland T
Sci Adv. 2022; 8(48):eade0459.
PMID: 36449623
PMC: 9710869.
DOI: 10.1126/sciadv.ade0459.
Highly different effects of phage therapy and antibiotic therapy on immunological responses of chickens infected with serovar Typhimurium.
Grabowski L, Wegrzyn G, Wegrzyn A, Podlacha M
Front Immunol. 2022; 13:956833.
PMID: 36211337
PMC: 9539762.
DOI: 10.3389/fimmu.2022.956833.
Subtherapeutic Doses of Vancomycin Synergize with Bacteriophages for Treatment of Experimental Methicillin-Resistant Infective Endocarditis.
Save J, Que Y, Entenza J, Resch G
Viruses. 2022; 14(8).
PMID: 36016414
PMC: 9412893.
DOI: 10.3390/v14081792.